Neonatal N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) treatment modifies the vulnerability to phenobarbital-and ethanol-evoked sedative-hypnotic effects in adult rats

Pharmacological Reports

Volumn 60, Issue 3, 2008, Pages 331-338

  Bortel, Aleksandra ^a   Słomian, Lucyna ^a   Nitka, Dariusz ^a   Świerszcz, Michał ^a   Jaksz, Mirella ^a   Adamus Sitkiewicz, Beata ^a   Nowak, Przemysław ^a   Jośko, Jadwiga ^a   Kostrzewa, Richard M ^b   Brus, Ryszard ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b East Tennessee State University   (United States)

Author keywords

Ethanol; GABA; Lesion; Noradrenergic; Phenobarbital; Rats

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ALCOHOL; NORADRENALIN; PHENOBARBITAL; SEROTONIN;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; DRUG SENSITIVITY; GABAERGIC SYSTEM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HYPNOTIC SUSCEPTIBILITY; MALE; NEWBORN PERIOD; NONHUMAN; NORADRENERGIC NERVE; NORADRENERGIC SYSTEM; PREFRONTAL CORTEX; RAT; RIGHTING REFLEX; SEDATION; SLEEP TIME;

EID: 49349103123     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V, Shiekhattar R et al.: Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res, 1991, 88, 47-75.
2. Berridge CW, Waterhouse BD: The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev, 2003, 42, 33-84.
3. Bortel A, Nitka D, Słomian L, Nowak P, Korossy E, Brus R, Kostrzewa RM: Neonatal noradrenergic lesion with DSP-4 modifies the convulsant effect of bicuculine and pentylenetetrazole in adult rats. Behavioral and biochemical studies. Ann Acad Med Siles, 2008 (in press).
4. Bortel A, Nowak P, Brus R: Neonatal DSP-4 treatment modifies GABA-ergic neurotransmission in the prefrontal cortex of adult rats. Neurotox Res, 2008 (in press).
5. Brus R, Nowak P, Labus Ł, Bortel A, Dabrowska J, Kostrzewa RM: Neonatal lesion of noradrenergic neurons in rat brain: interaction with the dopaminergic system. Pol J Pharmacol, 2004, 56, 232.
6. Curran MA, Newman LM, Becker GL: Barbiturate anesthesia and alcohol tolerance in a rat model. Anesth Analg, 1988, 67, 868-871.
7. Członkowski A, Kostowski W, Jerlicz M: Hexobarbital sleeping time in the rat: effects of isolation and lesions of the locus coeruleus. Pol J Pharmacol Pharm, 1976, 28, 609-613.
8. Dahlström A, Fuxe K: Localization of monoamines in the lower brain stem. Experientia, 1964, 20, 398-399.
9. Danhof M, Levy G: Kinetics of drug action in disease states. V. Acute effect of urea infusion on phenobarbital concentrations in rats at onset of loss of righting reflex. J Pharmacol Exp Ther, 1985, 232, 430-444.
10. 1A autoreceptors induced by neonatal DSP-4 treatment. Eur Neuropsychopharmacol, 2007, 17, 129-137.
11. Donzati BA, Yamamoto BK: An improved and rapid HPLC-EC method for the isocratic separation of amino acid neurotransmitters from brain tissue and microdialysis perfusates. Life Sci, 1988, 43, 913-922.
12. 2- and beta-adrenergic receptors in the rat after DSP-4, a selective nor-adrenergic neurotoxin. Neuroscience, 1983, 9, 889-898.
13. Erwin VG, Radcliffe R, Deitrich RA: Neurotensin levels in specific brain regions and hypnotic sensitivity to ethanol and pentobarbital as a function of time after haloperidol administration in selectively bred rat lines. J Pharmacol Exp Ther, 2001, 299, 698-704.
14. Fontana DJ, McMiller LV, Commissaris RL: Depletion of brain norepinephrine: differential influence on anxiolyic treatment effects. Psychopharmacology (Berl), 1999, 143, 197-208.
15. Giorgi FS, Mauceli G, Blandini F, Ruggieri S, Paparelli A, Murri L, Fornai F: Locus coeruleus and neuronal plasticity in a model of focal limbic epilepsy. Epilepsia, 2006, 47, Suppl 5, 21-25.
16. Haglund M, Sjöbeck M, Englund E: Locus ceruleus degeneration is ubiquitous in Alzheimer's disease: possible implications for diagnosis and treatment. Neuropathology, 2006, 26, 528-532.
17. Hara K, Yanagihara N, Minami K, Hirano H, Sata T, Shigematsu A, Izumi F: Dual effects of intravenous anesthetics on the function of norepinephrine transporters. Anesthesiology, 2000, 93, 1329-1335.
18. Haughey HM, Kaiser AL, Johnson TE, Bennett B, Sikela JM, Zahniser NR: Norepinephrine transporter: a candidate gene for initial ethanol sensitivity in inbred long-sleep and short-sleep mice. Alcohol Clin Exp Res, 2005, 29, 1759-1768.
19. 2+ channels. Neurosci Lett, 2000, 291, 175-178.
20. Jaim-Etcheverry G, Zieher LM: DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. Brain Res, 1980, 188, 513-523.
21. Jonsson G, Hallman H, Sundstrom E: Effects of the noradrenaline neurotoxin DSP4 on the postnatal development of central noradrenaline neurons in the rat. Neuroscience, 1982, 7, 2895-2907.
22. Kawahara Y, Kawahara H, Westerink BH: Tonic regulation of the activity of noradrenergic neurons in the locus coeruleus of the conscious rat studied by dual-probe microdialysis. Brain Res, 1999, 823, 42-48.
23. LaBuda CJ, Fuchs PN: Catecholamine depletion by reserpine blocks the anxiolytic actions of ethanol in the rat. Alcohol, 2002, 26, 55-59.
24. Lee HS, Kim MA, Waterhouse BD: Retrograde double-labeling study of common afferent projections to the dorsal raphe and the nuclear core of the locus coeruleus in the rat. J Comp Neurol, 2005, 481, 179-193.
25. Manns ID, Lee MG, Modirrousta M, Hou YP, Jones BE: Alpha 2 adrenergic receptors on GABAergic, putative sleep-promoting basal forebrain neurons. J Neurosci, 2003, 18, 723-727.
26. Matsumoto K, Kohno SI, Ojima K, Watanabe H: Flumazenil but not FG7142 reverses the decrease in pentobarbital sleep caused by activation of central noradrenergic systems in mice. Brain Res, 1997, 754, 325-328.
27. 2-Adrenoceptor-mediated presynaptic modulation of GABAergic transmission in mechanically dissociated rat ventrolateral preoptic neurons. J Neurophysiol, 2003, 89, 1640-1648.
28. Medina JH, Novas ML: Parallel changes in brain flunitrazepam binding and density of noradrenergic innervation. Eur J Pharmacol, 1983, 88, 377-382.
29. Narabayashi H: Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease. Adv Neurol, 1999, 80, 501-504.
30. Noguchi M, Kawai Y. Sleeping time after phenobarbital treatment and the brain levels of gamma-aminobutyric acid and phenobarbital at the regaining of righting response point in ethionine-induced liver-disordered mice. J Toxicol Sci, 1996, 21, 113-123.
31. Nowak P, Labus L, Kostrzewa RM, Brus R: DSP-4 prevents dopamine receptor priming by quinpirole. Pharmacol Biochem Behav, 2006, 84, 3-7.
32. Ojima K, Matsumoto K, Tohda M, Watanabe H: Hyper-activity of central noradrenergic and CRF systems is involved in social isolation-induced decrease in pentobarbital sleep. Brain Res, 1995, 684, 87-94.
33. Pashkov VN, Hemmings HC: The effects of general anesthetics on norepinephrine release from isolated rat cortical nerve terminals. Anesth Analg, 2002, 95, 1274-1281.
34. Paterson NE, Markou A: Animal models and treatments for addiction and depression co-morbidity. Neurotox Res, 2007, 11, 1-32.
35. Paul V, Ekambaram P: Effects of sodium nitroprusside, a nitric oxide donor, on γ-aminobutyric acid concentration in the brain and on picrotoxin-induced convulsions in combination with phenobarbitone in rats. Pharmacol Biochem Behav, 2005, 80, 363-370.
36. 2-adrenoceptors which regulate the synthesis and release of noradrenaline in the rat brain. Pharmacol Toxicol, 2001, 88, 152-158.
37. Pudovkina OL, Kawahara Y, de Vries J, Westerink BH: The release of noradrenaline in the locus coerulcus and prefrontal cortex studied with dual-probe microdialysis. Brain Res, 2001, 906, 38-45.
38. Pudovkina OL, Westerink BH: Functional role of alphal -adrenoceptors in the locus coeruleus: A micro-dialysis study. Brain Res, 2005, 1061, 50-56.
39. Ramos BP, Arnsten AF: Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther, 2007, 113, 523-536.
40. Ressler KJ, Nemeroff CB: Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry, 1999, 46, 1219-1233.
41. Samad N, Perveen T, Haider S, Haleem MA, Haleem DJ: Inhibition of restraint-induced neuroendocrine and serotonergic responses by buspirone in rats. Pharmacol Rep, 2006, 58, 636-642.
42. Smith S, Sharp T: Measurement of GABA in rat brain microdialysates using o-phthaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection. J Chromatogr B, 1994, 652, 228-233.
43. Spuhler K, Gerhardt G, Palmer MR: CNS monoamine levels and the effect of DSP4 on ethanol-sensitivity in LS and SS mice. Alcohol, 1987, 4, 419-424.
44. A signaling. Pharmacol Rep, 2006, 58, 820-826.
45. Suzdak PD, Gianutsos G: GABA-noradrenergic interaction: evidence for differential sites of action for GABA-A and GABA-B receptors. J Neural Transm, 1985, 64, 163-172.
46. Wang Y, Freund RY, Palmer MR: Potentiation of ethanol effects in cerebellum by activation of endogenous nor-adrenergic inputs. J Pharmacol Exp Ther, 1999, 288, 211-220.
47. Youdim, MB, Bakhle YS: Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol, 2006, 147, 287-296.